Jonathan Meyer, MD

Anticholinergic Burden KOL Roundtable Video Series

Videos

Overview of Anticholinergic Medications

11/25/2024

Desiree Matthews , PHMNP-BC;

Jonathan Meyer , MD;

Leslie Citrome , MD;

This roundtable video featuring Desiree Matthews, Jonathan Meyer, and Leslie Citrome provides background on the use of anticholinergic medications in psychiatry.

This roundtable video featuring...

11/25/2024

Psych Congress Network

Videos

The Anticholinergic Burden of Psychotherapeutics

11/25/2024

Desiree Matthews , PHMNP-BC;

Jonathan Meyer , MD;

Leslie Citrome , MD;

This roundtable video featuring Desiree Matthews, Jonathan Meyer, and Leslie Citrome discusses the patient burden of anticholinergic drugs.

This roundtable video featuring...

11/25/2024

Psych Congress Network

Videos

Practical Strategies for Anticholinergic Deprescribing

11/25/2024

Desiree Matthews , PHMNP-BC;

Jonathan Meyer , MD;

Leslie Citrome , MD;

This roundtable video featuring Desiree Matthews, Jonathan Meyer, and Leslie Citrome discusses practical strategies for anticholinergic deprescribing.

This roundtable video featuring...

11/25/2024

Psych Congress Network

Videos

Unpacking Negative Symptoms, Medication Adverse Effects, and Emerging Schizophrenia Treatments

11/11/2024

Jonathan Meyer , MD;

Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.

Jonathan Meyer, MD, offers his...

11/11/2024

Psych Congress Network

Clinician-Reported Patient Awareness of Symptoms and Severity of Tardive Dyskinesia in Patients Prescribed VMAT2 Inhibitors

Background: Vesicular monoamine transporter 2 (VMAT2) inhibitors including valbenazine are first-line therapies for tardive dyskinesia (TD), a persistent movement disorder associated with...

Leslie Lundt , MD;

Chuck Yonan , PharmD;

Rahul Dhanda , PhD;

Jonathan Meyer , MD;

Betsy Benning ;

Ericha Franey , PhD;

Edward Goldberg , MD;

10/18/2020

Weight Gain and Treatment Interruptions With Second-Generation Oral Antipsychotics: Analysis of Real-World Data Among Patients With Schizophrenia or Bipolar I Disorder

Among patients with schizophrenia (SZ) and bipolar I disorder (BD-I) treated with second-generation antipsychotics (SGAs), clinically-significant weight gain (CSWG) and treatment interrup...

Hannah Cummings , PhD;

Gregory Donadio , MA;

Thomas Brecht , MS;

Leona Bessonova , PhD;

Amy O'Sullivan , PhD;

David McDonnell , MD;

Jonathan Meyer , MD;

Kathleen Mortimer , ScD, MPH;

Michael Doane , PhD;

Henry Cheng , MA, MPH;

10/08/2020

A New Method for Initiating Treatment With the Long-acting Antipsychotic Aripiprazole Lauroxil

BACKGROUND: Significant delay can occur between the first dose of a long-acting injectable (LAI) antipsychotic and achievement of efficacious plasma concentrations, which is usually addre...

Lisa L. von Moltke , MD, FCPP;

Bhaskar Rege , PhD, BPharm;

Peter J. Weiden , MD, PhD;

Jonathan Meyer , MD;

Rakesh Jain , MD, MPH, RD;

Angela Wehr , PhD;

03/01/2019